Colleluori’s randomized controlled trial demonstrated that a combination of aromatase inhibitor (AI) therapy and WL significantly improved the hormonal profile of obese men with hypogonadotropic hypogonadism (HHG) [38]. The gene discussed is CYP19A1; the disease is hypogonadotropic hypogonadism.